5 results
The primary objective is to investigate if there is an incremental inhibiting effect on MSNA by increasing dosage valsartan above the presently advised dosage. We hypothesize that there will be a further decrease in MSNA as compared to the MSNA…
Primary objective To investigate the safety and tolerability of CCS1477 as monotherapy and in combination.
The main objective of this Phase IIa/b study is to demonstrate the effectof zibotentan on HVPG, and that dapagliflozin can mitigate fluid retention safety concernsregarding its use in this population.
· To evaluate the effect of zibotentan anddapagliflozin in combination and alone versusplacebo on UACR.
Primary- Continuation of treatment- SafetySecondairy- Documentation of tolerability